NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
तुलना करने के लिए मीट्रिक्स | NEXI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNEXIपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.6x | −0.6x | |
PEG अनुपात | 0.00 | 0.06 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 9.2x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 146.0% | 45.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 12.3% | 6.5% | अनलॉक करें |